The research, led by Hui Jeong An, Sung Hwan Cho, and colleagues at CHA University and CHA Bundang Medical Center, with corresponding authors Jin-Bae Kim of Kyung Hee University Hospital and Nam Keong Kim of CHA University, focused on four specific microRNAs: miR-10a, miR-30c, miR-181a, and miR-499b. MicroRNAs are short, non-coding RNA molecules, roughly eighteen to twenty-five nucleotides in length, that do not encode proteins themselves. Instead, they act as fine-tuners of gene expression. After being transcribed from the genome and processed through a well-characterized cellular machinery involving enzymes such as Drosha and Dicer, mature microRNAs are loaded into the RNA-induced silencing complex, where they bind to target sequences, typically within the three-prime untranslated region of messenger RNAs. This binding either promotes degradation of the target transcript or blocks its translation into protein. Because a single microRNA can regulate dozens or even hundreds of target genes, changes in microRNA sequence or abundance can ripple outward across entire biological pathways.

What makes microRNAs especially interesting from a genetic standpoint is that their genes themselves can harbor single nucleotide polymorphisms, or SNPs, which are positions in the DNA sequence where a single letter of the genetic code varies between individuals. When such a variant sits within the mature microRNA sequence or its precursor, it can alter how the microRNA folds, how it is processed, or which messenger RNAs it binds. In effect, these polymorphisms function as heritable knobs that dial the activity of gene regulatory networks up or down. Previous studies, including earlier work by some of the same Korean investigators on miR-146a, miR-149, miR-196a2, and miR-499 in the context of recurrent pregnancy loss, have suggested that such variants could plausibly influence reproductive outcomes, although findings across populations have often been inconsistent.

To interrogate this question systematically, the team enrolled 169 Korean women diagnosed with recurrent implantation failure and compared them against 281 fertile controls. Genomic DNA was extracted from peripheral blood samples, and the researchers genotyped four variants, denoted miR-10a A>T, miR-30c A>G, miR-181a T>C, and miR-499b A>G, using two complementary laboratory techniques: polymerase chain reaction with restriction fragment length polymorphism analysis, a classic method in which a variant either preserves or abolishes a restriction enzyme’s cutting site so that genotypes can be read from fragment sizes on a gel, and real-time polymerase chain reaction, which offers a faster, fluorescence-based genotyping readout. The study protocol received ethical approval from the Institutional Review Board of CHA Bundang Medical Center, and all participants provided written informed consent.

The first and perhaps most important analytical result was a negative one: when the researchers compared the overall RIF group with fertile controls, none of the four microRNA polymorphisms showed a statistically significant independent association with implantation failure risk. This kind of null result is common in complex-disease genetics and underscores why single-variant analyses frequently fail to capture the biology of multifactorial conditions. However, the picture changed when the investigators stratified the RIF group by clinical and laboratory characteristics. Among women who had experienced four or more failed implantation attempts, carriers of the miR-499b AG genotype showed a significantly elevated risk, with an adjusted odds ratio of 1.908 and a p-value of 0.021. Similarly, the miR-181a TC plus CC genotypes appeared to raise risk specifically among women with lower platelet counts, while the miR-30c AG plus GG genotypes consistently behaved in a protective manner, an effect that was particularly striking in subgroups of women with a body mass index of 25 kilograms per square meter or higher, where the adjusted odds ratio fell to 0.104, and in women with shorter activated partial thromboplastin times, where the adjusted odds ratio was 0.216.

These subgroup signals gain biological plausibility from what is already known about the targets of these microRNAs. PAI-1, the plasminogen activator inhibitor-1, is the principal inhibitor of tissue-type and urokinase-type plasminogen activators in the fibrinolytic system, and it is a confirmed target of miR-10a, miR-30c, and miR-181a, and a predicted target of miR-499b. PAI-1 is far from an arbitrary choice in a reproduction study. Successful implantation requires that trophoblast cells invade the endometrium in a tightly regulated fashion, a process that depends on a carefully choreographed balance between extracellular matrix degradation and coagulation control. Prior literature has linked PAI-1 expression to endometrial receptivity, to the invasive capacity of endometrial cells, and to disorders of female reproduction ranging from endometriosis to recurrent pregnancy loss. The PAI-1 4G/5G polymorphism has itself been studied in relation to implantation outcomes, and experimental work in endothelial and endometrial cancer cell models has shown that microRNAs of the 181 family and miR-10a can modulate PAI-1 levels and thereby influence fibrinolysis and cellular invasion.

Because of this mechanistic connection, the Korean team went beyond the conventional single-variant association analysis and tested whether combinations of microRNA polymorphisms and PAI-1 genotypes interacted synergistically to shape RIF risk. This type of multilocus analysis is statistically delicate, since the number of possible genotype combinations grows exponentially with each additional locus, but it can reveal gene-gene interactions that no individual variant analysis would detect. The results were striking. A three-locus combination involving PAI-1 and miR-181a, denoted the A-T-C combination, was strongly associated with susceptibility to RIF, with an odds ratio of 2.644, a p-value of 0.002, and a false discovery rate corrected p-value of 0.014, indicating that the signal survived correction for multiple testing. Conversely, a different combination, the G-T-G pairing of PAI-1 with miR-30c, was found exclusively among the fertile controls and was associated with a strong protective effect, with an odds ratio of just 0.055, a p-value of 0.002, and a false discovery rate corrected p-value of 0.014. In other words, women carrying that particular genetic configuration were dramatically underrepresented among those who experienced repeated implantation failure.

The authors are appropriately measured about the interpretive limits of their work. Certain multilocus allele combinations involving PAI-1 did show suggestive associations with RIF risk, but the estimates for rare combinations came with wide confidence intervals and, as the researchers themselves emphasize, should be treated as exploratory hypotheses rather than established findings. Genetic association studies in reproductive medicine have a checkered history of promising signals that fail to replicate, particularly when sample sizes are modest, as is nearly inevitable in a condition defined by a specific and relatively uncommon clinical presentation. The RIF group in this study comprised 169 women, a substantial number for this field but still small by the standards of genome-wide association research, and the cohort was restricted to Korean women, which raises questions about generalizability across ethnic groups where allele frequencies and linkage patterns may differ.

Nevertheless, the conceptual contribution of the study is significant. By anchoring the analysis in a defined biological axis, microRNAs that regulate PAI-1, the investigators moved beyond blind variant scanning and toward a pathway-informed framework for understanding implantation genetics. The protective effect of miR-30c AG plus GG genotypes in women with higher BMI and shorter aPTT, the risk effect of miR-499b AG among women with the most failed cycles, and the strongly interacting PAI-1 and miR-181a haplotypes all point toward the same underlying biology: the coagulation and invasion machinery of the endometrium, fine-tuned by post-transcriptional regulation, appears to be one of the determinants of whether an embryo can successfully establish a pregnancy. This is consistent with endometrial transcriptomic studies showing that microRNA expression profiles within the window of implantation differ between women with repeated failure and fertile individuals.

What might this mean clinically, and what should happen next? In the near term, nothing in this study supports routine genetic screening of IVF patients for these microRNA variants, since none of the individual polymorphisms predicted risk in the overall population and the stratified findings require independent validation. But the longer-term implications are tantalizing. If future studies in larger, multiethnic cohorts confirm that PAI-1 and microRNA genotype combinations stratify implantation failure risk, such information could eventually inform personalized protocols, guiding decisions about anticoagulation, endometrial preparation, or the intensity of preimplantation evaluation for women at high genetic risk. The study also reinforces a broader lesson that is reshaping human genetics: regulatory variation, including variation within microRNA genes, matters as much as variation within protein-coding sequences, and it is the architecture of interactions, not the influence of any single variant, that most often distinguishes patients from controls. Funded in part by Korea’s National Research Foundation, the Korea Health Industry Development Institute, and related agencies, and conducted under rigorous ethical oversight, this work offers the fertility research community a carefully documented set of hypotheses and a demonstration that the genetics of implantation, like implantation itself, is fundamentally a story of cooperation among molecular players rather than the performance of any one actor.

Subject of Research: Association of microRNA polymorphisms and PAI-1 gene-gene interactions with recurrent implantation failure in Korean women

Article Title: Association of miRNA (miR-10a, miR-30c, miR-181a, and miR-499b) Polymorphisms and Their Interactions with PAI-1 in Recurrent Implantation Failure in Korean Women

Article References: An, H. J., Cho, S. H., Ko, J. E., Kim, J. H., Park, H. W., Kim, Y. R., Ahn, E. H., Kim, J.-B., & Kim, N. K. (2026). Association of miRNA (miR-10a, miR-30c, miR-181a, and miR-499b) Polymorphisms and Their Interactions with PAI-1 in Recurrent Implantation Failure in Korean Women. Reproductive Sciences. https://doi.org/10.1007/s43032-026-02188-3

Image Credits: AI Generated

DOI: 10.1007/s43032-026-02188-3

Keywords: recurrent implantation failure, microRNA, PAI-1, single nucleotide polymorphism, in vitro fertilization, fertility genetics, gene-gene interaction, miR-181a, miR-30c, fibrinolysis, endometrial receptivity, Korean women

To appreciate why the findings matter, it helps to understand what ATM actually does. Every day, human DNA is battered by damage from both inside and outside the cell: reactive oxygen species generated by metabolism, replication errors, hydrolysis, aging, ultraviolet radiation, and chemical exposures. Among the repair systems that respond, homologous recombination is the primary mechanism for fixing double-strand breaks, the most dangerous form of DNA injury. When both strands of the double helix snap, unrepaired lesions can trigger chromosomal abnormalities and mutagenic cascades that push cells toward malignancy. ATM sits at the command center of this response, and when it malfunctions, the consequences ripple through the entire genome.

The gene itself is a molecular heavyweight: it spans 66 exons and encodes a serine/threonine kinase whose active monomeric form weighs roughly 370 kilodaltons. When a double-strand break occurs, a sensor complex called MRN, composed of the MRE11, RAD50, and NBS1 proteins, recognizes the damage and recruits ATM to the site. Once there, ATM undergoes autophosphorylation and begins phosphorylating a battery of downstream effectors, including BRCA1, BRCA2, and CHEK2. CHEK2 acts to halt the cell cycle by inhibiting CDC25A, buying the cell time to repair. ATM also stabilizes p53, both directly and by degrading its suppressor MDMX, allowing p53 to upregulate p21 and enforce arrest at the G1/S or G2/M checkpoints. If damage proves irreparable, p53 flips the switch toward programmed cell death by activating genes such as BID, BAX, and PUMA.

Germline mutations in ATM have long been associated with ataxia-telangiectasia, an autosomal recessive syndrome marked by genomic instability, immunodeficiency, and heightened cancer predisposition. Beyond the syndrome, inherited ATM variants have been linked to pancreatic, esophageal, lung, melanoma, breast, ovarian, prostate, and bladder cancers, as well as certain lymphoma subtypes. Somatic ATM mutations appear most frequently in hematological malignancies, particularly lymphoid cancers, where frequencies range from 5 to 45 percent. Among myeloid clonal disorders, the numbers are far lower: under 5 percent in AML, about 0.4 percent in MDS, and rare in chronic myeloproliferative subsets. That relative rarity, the review argues, has led researchers to underestimate ATM’s clinical significance in these diseases.

To address that gap, the Brazilian team conducted a PROSPERO-registered systematic review, following the PRISMA 2020 guidelines and searching PubMed, SciELO, and LILACS for peer-reviewed studies published between January 2010 and August 2025. The initial search returned 80 records. After removing duplicates, screening titles and abstracts, and excluding preclinical murine and in vitro studies, case reports, letters, reviews, and unrelated diseases, only ten original studies survived the filter. Methodological quality assessment classified two studies as low risk of bias, thanks to large samples and robust observational designs, while the remainder carried moderate risk due to small cohorts, single-center recruitment, missing validation data, and heterogeneous methods for assessing ATM alterations.

Five of the ten studies focused on MDS, the most common bone marrow cancer and the disorder where ATM’s footprint is most visible. In the largest investigation, covering 232 MDS patients across three cohorts analyzed with pyrosequencing, real-time PCR, immunohistochemistry, and next-generation sequencing, ATM showed the highest methylation levels among patients who progressed to acute leukemia. Those who transformed to AML exhibited roughly double the methylation rate of those who did not, with a median methylation score of 4.97 versus 2.45, a statistically significant difference. The same team also mined 7,583 MDS cases from the cBioportal database and found ATM frequently altered by frameshift and missense mutations, most classified as likely oncogenic, reinforcing the picture of a gene silenced or downregulated during disease evolution.

Other MDS studies added nuance. A prospective analysis of 31 young, low-risk MDS patients with neutropenia and thrombocytopenia identified only heterozygous ATM variants of undetermined significance, with no clear impact on survival or transfusion needs. Two studies examining ATM polymorphisms and expression found that the rs228593 single nucleotide polymorphism was associated with increased ATM expression, particularly among patients at high or very high risk of leukemic progression, while ATM expression was reduced in hypocellular MDS but showed no survival correlation. A fifth study measuring DNA damage response proteins by immunofluorescence and immunohistochemistry in 74 patients found no significant relationship between phosphorylated ATM and clinical outcomes, leaving the prognostic value of ATM in MDS genuinely contested.

Three studies addressed AML, and here the mechanisms came into sharper focus. In two pediatric cohorts, researchers showed that ATM expression was suppressed by microRNAs: miR-100 in 30 children aged up to 14 years, and miR-181a in 57 children with a mean age of seven. When ATM was knocked down, cells accelerated through the G1/S checkpoint and myeloblast proliferation increased, offering a direct mechanistic link between ATM silencing and leukemic growth. MicroRNAs of the 181a/b cluster are known to be triggered by the PML/RARα fusion in acute promyelocytic leukemia, where they suppress the tumor suppressor RASSF1A and block granulocytic differentiation; treatment with all-trans-retinoic acid lowers these microRNAs, restores RASSF1A, and drives leukemic cells into arrest and apoptosis. In adults, a study of 307 AML patients genotyped for 42 variants across 15 DNA repair genes found that the ATM 4138C>T variant (rs3092856) was associated with striking chemotherapy refractoriness, seven of eight carriers resisted treatment, and inferior overall survival, a median of 7 versus 11 months, making it the largest AML cohort examining ATM polymorphisms to date.

Evidence from chronic myeloid leukemia and other myeloproliferative neoplasms remains thin but provocative. In a study of 476 CML patients in India, the ATM polymorphisms −5144A>T (rs228589) and C4138T (rs3092856) were associated with higher CML risk and worse scores on the EUTOS prognostic scale. A separate whole-genome sequencing study of 64 individuals from families with inherited myeloproliferative neoplasms, including essential thrombocythemia, polycythemia vera, and primary myelofibrosis, identified the germline ATM variant L2307F in some cases, although genomic instability was not evident across disease subtypes. Additional variants reported in MDS cohorts, including c.5753G>C, c.346A>G, and c.4060C>A, round out a growing but still fragmentary catalog of ATM alterations across the myeloid spectrum.

The review’s authors are candid about the limits of the evidence. The ten eligible studies varied widely in design, sample size ranging from 31 to 232 patients, laboratory methods, and measured outcomes, which precluded quantitative meta-analysis and left the overall evidence at low-to-moderate quality, best described as hypothesis-generating. Publication bias, retrospective designs, and population variability further constrain the inferences. Yet the authors argue the implications are clear enough to demand action: ATM alterations, spanning methylation, expression loss, somatic mutations, and inherited polymorphisms, behave as clinically relevant biomarkers across MDS, AML, and MPN, and the rs3092856 variant in particular emerges as a recurring thread linking chemoresistance and poor survival. Rather than treating ATM merely as a prognostic marker, the researchers call for multicenter studies with standardized methods, functional characterization of the mutations, integration of ATM status into treatment-oriented molecular panels, and exploration of therapeutic vulnerabilities, especially DNA repair inhibitors and synthetic lethality approaches that could finally convert this guardian gene’s failures into therapeutic opportunities.

Subject of Research: The prognostic and biological impact of ATM gene alterations in myeloid malignancies including MDS, AML, and myeloproliferative neoplasms

Article Title: ATM mutations in myelodysplastic neoplasms, acute myeloid leukemia, and myeloproliferative neoplasms: a systematic review

Article References: Laurindo, L. O., Parente, M. L. B., Sasahara, G. L., Goes, J. V. C., Sampaio, L. R., Pinheiro, Y. V., & Pinheiro, R. F. (2026). ATM mutations in myelodysplastic neoplasms, acute myeloid leukemia, and myeloproliferative neoplasms: a systematic review. Medical Oncology, 43(11), Article 300. https://doi.org/10.1007/s12032-026-03378-4

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03378-4

Keywords: ATM gene, myelodysplastic neoplasms, acute myeloid leukemia, myeloproliferative neoplasms, DNA damage response, DNA methylation, genomic instability, rs3092856, miR-181a, chemoresistance, systematic review, precision medicine